1-methyl-1,2,3,4-tetrahydroisoquinoline has been researched along with Basal Ganglia Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antkiewicz-Michaluk, L; Bojarski, A; Michaluk, J; Romaska, I; Vetulani, J; Wardas, J | 1 |
1 other study(ies) available for 1-methyl-1,2,3,4-tetrahydroisoquinoline and Basal Ganglia Diseases
| Article | Year |
|---|---|
Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone.
Topics: Animals; Basal Ganglia Diseases; Brain Chemistry; Dopamine; Injections; Injections, Subcutaneous; Male; Medial Forebrain Bundle; Neostriatum; Nerve Degeneration; Neuroprotective Agents; Presynaptic Terminals; Rats; Rats, Wistar; Rotenone; Serotonin; Stereotaxic Techniques; Substantia Nigra; Tetrahydroisoquinolines; Uncoupling Agents | 2004 |